Antidysrhythmic therapy is used to suppress supraventricular and ventricular dysrhythmias, thus relieving symptoms and reducing the risk of sudden cardiac death. The Cardiac Arrhythmia Suppression Trial (CAST) found an increased mortality rate in a group of patients treated with two antidysrhythmic agents. This result has had a profound impact on the prescribing and monitoring of antidysrhythmic therapy. Prodysrhythmia is a frequent and serious complication of antidysrhythmics and is unpredictable. Assessment of benefit versus risk of drug therapy for each patient is recommended. The nurse’s knowledge of antidysrhythmic pharmacology, including symptoms that indicate adverse reactions, and prodysrhythmia influences the patient outcome
This content is only available as a PDF.
©1992 American Association of Critical-Care Nurses